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Abstract
Introduction
The generation of Rho-0 cells requires the use of an immortalization process, or tumor cell
selection, followed by culture in the presence of ethidium bromide (EtBr), incurring the
drawbacks its use entails. The purpose of this work was to generate Rho-0 cells using
human mesenchymal stem cells (hMSCs) with reagents having the ability to remove mito-
chondrial DNA (mtDNA) more safely than by using EtBr.
Methodology
Two immortalized hMSC lines (3a6 and KP) were used; 143B.TK-Rho-0 cells were used as
reference control. For generation of Rho-0 hMSCs, cells were cultured in medium supple-
mented with each tested reagent. Total DNA was isolated and mtDNA content was mea-
sured by real-time polymerase chain reaction (PCR). Phenotypic characterization and
gene expression assays were performed to determine whether 3a6 Rho-0 hMSCs maintain
the same stem properties as untreated 3a6 hMSCs. To evaluate whether 3a6 Rho-0
hMSCs had a phenotype similar to that of 143B.TK-Rho-0 cells, in terms of reactive oxygen
species (ROS) production, apoptotic levels and mitochondrial membrane potential (Δψm)
were measured by flow cytometry and mitochondrial respiration was evaluated using a
SeaHorse XFp Extracellular Flux Analyzer. The differentiation capacity of 3a6 and 3a6
Rho-0 hMSCs was evaluated using real-time PCR, comparing the relative expression of
genes involved in osteogenesis, adipogenesis and chondrogenesis.
Results
The results showed the capacity of the 3a6 cell line to deplete its mtDNA and to survive in
culture with uridine. Of all tested drugs, Stavudine (dt4) was the most effective in producing
3a6-Rho cells. The data indicate that hMSC Rho-0 cells continue to express the character-
istic MSC cell surface receptor pattern. Phenotypic characterization showed that 3a6 Rho-
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0 cells resembled 143B.TK-Rho-0 cells, indicating that hMSC Rho-0 cells are Rho-0 cells.
While the adipogenic capability was higher in 3a6 Rho-0 cells than in 3a6 cells, the osteo-
genic and chondrogenic capacities were lower.
Conclusion
Among the drugs and conditions tested, the use of d4t was the best option for producing
Rho-0 cells from hMSCs. Rho-0 cells are useful for studying the role of mitochondria in
hMSC differentiation.
Introduction
Mitochondrial dysfunction is central to the pathogenesis of somemonogenic syndromes.
Examples of these syndromes include the MELAS syndrome (mitochondrial encephalomyopa-
thy, lactic acidosis, and stroke-like episodes caused by mutation of mitochondrial transfer
RNAs) [1,2] and Leigh’s disease (caused by mutations in genes related to oxidative phosphory-
lation) [1,3,4]. In addition, there is an emerging recognition that disorderedmitochondrial
dynamics contribute to the pathogenesis of complex diseases not classically considered to
involve mitochondria; these diseases include cancer [5,6], cardiovascular disease [7,8,9], neuro-
degenerative diseases [10,11] and rheumatic diseases [12–15].
In the last century, immortal cell lines have been developed that are devoid of mitochondrial
DNA (mtDNA) (Rho-0 (ρ0)) [16]. Rho-0 cells are highly valid tools to study human mitochon-
drial disorders because they can be used to develop a cytoplasmic hybrid (cybrid)model. This
model is interesting because it allows the study of the real role of mtDNA single nucleotide
polymorphisms (SNPs) with the same nuclear DNA background.Mitochondrial functions are
controlled by both mtDNA and nuclear DNA; cybrids are useful for the difficult task of identi-
fying whether the mitochondrial or nuclear genome is responsible for a particularmitochon-
drial defect. Cybrids are constructed by fusing a cell without a nucleus that harbors the
mtDNA of interest with Rho0 cells in which endogenousmtDNA has been depleted. Cybrid
cell lines have been successfully used to explore the contribution of mitochondrial dysfunction
and mtDNA gene mutations to the pathogenesis of diseases, such as Parkinson's Syndrome.
Because disease cybrids can be generated from patients at all stages of a disease, they provide a
window into early stages of disease pathogenesis not available from pathological specimens.
Therefore, Rho-0 cells represent an important tool for development of cellular models of dis-
ease, for studying the pathogenesis of some diseases, or to test the toxic effects of drugs.
The generation of Rho-0 cells is challenging and requires the use of an immortalization pro-
cess followed by a lengthy culture in the presence of various low-dose drugs. Surprisingly, this
does not ensure the complete depletion of mtDNA from the cells. The use of ethidium bromide
(EtBr) is the most common and successful procedure to generate Rho-0 cells because EtBr pos-
sesses high capacity to intercalate into the mitochondrial double-strandedDNA, thereby inter-
fering with enzymes of the replication machinery. However, mutagenic effects of EtBr on the
nuclear genome cannot be excluded [17].
At present, most Rho-0 cells are obtained from tumor cells, with all the drawbacks that this
entails [18–20]. Mesenchymal stem cells (MSCs) are stromal cells that were originally isolated
from the adherent portion of bonemarrow [21,22]. MSCs grow as spindle-shaped cells display-
ing a colony-forming capability in low density cultures and are non-hematopoietic and non-
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endothelial.MSCs can be propagated throughmultiple passages in cell culture and differentiate
into the standard osteogenic, adipogenic and chondrogenic lineages in appropriate media [23].
Because of the adverse effects of EtBr and the inconvenience of using tumor cells to generate
Rho cells, we conducted this experiment to attempt to improve these limitations. We first
tested some reagents with the ability to remove mtDNA more safely than EtBr. To this end, we
selected substances with the capacity to decrease the mtDNA copy number of cells by inhibit-
ing mitochondrial oxidative phosphorylation, interfering with mtDNA replication, or inhibit-
ing polymerase γ [24–27]. Subsequently, we replaced tumor cell lines with hMSCs from bone
marrow. Although hMSCs are readily isolated but they have limited ability to expand under
standard conditions or with increasing age [28,29] and rapidly senesce in culture with
restrictedmultilineage differentiation capacity [30,31]. For this reason we used two immortal-
ized hMSC lines, KP and 3a6 [32,33].
Material and Methods
Cell culture of hMSCs
Two immortalizedhuman mesenchymal/stromal cell lines (hMSCs) were used in this work,
the KP and 3a6 hMSC lines. Both hMSC lines were kindly provided by Dr Hung’s group.
KP cells were developed by Hung’s group using hMSC isolated from a bonemarrow (BM)
aspirate of a 61-year-old female donor in the Veteran´s General Hospital-Taipei. The KP cell
line was immortalizedusing a retroviral vector transduction that expressed HPV16 E6/E7 [32].
KP cells were then transfected with phTERT-IRES2-EGFP to obtain the 3a6 cell line [33]. KP
cells were cultured using the Mesenchymal Stem Cell Growth Medium Bullet Kit (LONZA,
Biowhittaker, Viviers, Belgium), while 3a6 cell lines were grown in Dulbecco´sModified Eagle
´s Medium-LowGlucose (DMEM-LG) (GIBCO, Grand Island, NY, USA) supplemented with
10% fetal bovine serum (FBS), penicillin (100 U/ml), streptomycin (100 μg/ml) (P/S; Gibco,
Paisley, United Kingdom) and 2 mM L-glutamine (GlutaMax, GIBCO).
The study was approved by the Ethics Committee of the GalicianHealth Administration.
Rho-0 cell culture
The 143B.TK-Rho-0 cell line used in all the experiments as a reference control was kindly pro-
vided by Dr Garesse´s group. It was obtained from a human osteosarcoma cell line (143B.TK-)
subsequently treated for 6–8 weeks with low dosage (50 ng/ml) EtBr. 143B.TK-Rho-0 cells
were maintained in DMEM containing 10% FBS, P/S and 50 mg/ml uridine (Sigma-Aldrich,
St. Louis, MO, USA). Rho-0 cells need specific supplementation with uridine to sustain their
viability. The uridine satisfies the energy demand of these cells and possibly generates pyrimi-
dine despite the inhibition of dihydroorotate dehydrogenase (DHODH), a key enzyme in the
biosynthesis of pyrimidine.
In all cases the mediumwas changed twice a week and subculture was performed after the
cells reached 80% confluency. Cells were maintained in a 5% CO2 and 90% humidified atmo-
sphere at 37°C.
Generation of hMSC Rho-0 cells
Cells were plated in a 6-multiwell plate (MW-6; Corning Incorporated, Kennebunk, ME, USA)
(8x104 cells per well) and cultured in the appropriate medium for each type, following the
same procedure (Fig 1). Cells were maintained for 24 hours in the appropriate culture medium
before the mediumwas supplemented with each tested condition: 3,8-Diamino-5-ethyl-6-phe-
nylphenanthridinium bromide (Ethidium bromide, EtBr) (Sigma-Aldrich), Rhodamine 6g
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(Rd6g) (Invitrogen, Waltham, MA, USA), 1-methyl-4-phenylpyridinium (MPP+), Zidovudine
(AZT, 3´-azido-3´-deoxythymidine) or Stavudine (d4t; 2'-3'-didehydro-2'-3'-dideoxythymi-
dine) (Sigma-Aldrich) (Table 1). Culture media were always supplemented with uridine (50
mg/ml). Drug stocks were prepared following the manufacturers' instructions and replenished
at each medium change. The stocks were stored at -20°C between doses and new stocks were
prepared before each experiment.
In all the experiments, cells with no treatment were used as controls to determine the base-
line levels of mtDNA for each cell type. Cells cultured with EtBr were used as positive controls
to assess the capacity of the different cell lines to survive with very low levels of mtDNA. 143B.
TK-Rho-0 cells were used as a reference for the mtDNA content characteristic of a standard
Rho-0 line.
DNA isolation and quantification of mtDNA copy number
Total DNA from untreated cells (5x105) and cells cultured with the test compounds (1x105)
was isolated using a commercial kit (Qiagen,Manchester, UK), following the manufacturer's
instructions.
The mtDNA content was measured by real-time polymerase chain reaction (PCR) using the
LightCycler1 480 II (Roche Applied Science,Mannhein, Germany). The targeted genes were
the mitochondrial12S ribosomal gene (12S-rRNA) and the nuclear gene RNAseP. Duplicate
DNA samples were amplified in parallel in a final volume of 20 μL containing 50 ng DNA,
10 μL of LightCycler1 480 Sybr Green I Master (Roche Diagnostics),0.3 μM primers for 12S-
rRNA (forward 5´-CCACGGGAAACAGCAGTGAT-3', reverse 5´-CTATTGACTTGGGTT
AATCGTGTGA-3') and 0.3 μM RNAseP primers (forward: 5´-GCACTGAGCACGTTGAG
AGA-3'; reverse: 5´-CCAGTCGAAGAGCTCCAGA-3') with H2O to reach the final volume.
The mixture was amplified by 50 cycles at 95°C for 10 seconds, 60°C for 15 seconds and 72°C
for 10 seconds; with a final extension of 72°C for 1 minute. The specificity of all reactions was
determined by a melting point curve analysis using one cycle at 95°C for 5 seconds and 65°C
for 1 minute followed by a heating step at 97°C with continuous fluorescence acquisition. For
determiningmtDNA copy number, an independent standard curvewas generated for each
gene (12S-rRNA and RNAseP). The total mtDNA copy number was determined from the Ct
values and was extrapolated into the external standard curve. The concentration for each gene
was obtained in the analyzed samples. MtDNA copy number values were expressed by the
ratio 12S rRNA/RNAseP. To normalize the values between all experiments, we established the
mtDNA copy number using the control cells (cells without treatment) as 100%.
Fig 1. Work flow for generating Rho-0 Cells from human mesenchymal stem cells (hMSCs). d4t = Stavudine;
mtDNA = mitochondrial DNA; Q-PCR = quantitative polymerase chain reaction; 12S-rRNA = mitochondrial12S ribosomal
gene; RNAseP = nuclear gene.
doi:10.1371/journal.pone.0164199.g001
Table 1. List of drugs analyzed to deplete mitochondrial DNA (mtDNA) in human mesenchymal stem cell lines (hMSCs).
Drug Concentration Time (Hours)
Etidium bromide (EtBr) 1 mM, 500 nM, 100 nM 168
Rhodamine-6g (Rd6g) 1 μg/ml, 3 μg/ml, 5 μg/ml 24–168
1-methyl-4-phenylpyridinium (MPP+) 25 μM, 0.5 mM, 1 mM 72
Zidovudine (AZT) 10 μM, 20 μM, 0.5 mM 96–240
Stavudine (d4t) 5 μM, 10 μM, 100 μM, 0.5 mM 96–240
doi:10.1371/journal.pone.0164199.t001
Rho-0 Mesenchymal Stem Cell
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Clone selection
For the 3a6 cell line, clone selectionwas performed in the presence of d4t at 0.5 mM over a
240-hour period (Fig 1). Cells were plated in a P-100 dish at very low density; 90 cells were
plated (limit dilution) in DMEM-LG supplemented with 10% FBS, P/S, 0.5 mM d4t and 50
mg/ml uridine. After 24 hours cells were examined under an optical microscope and isolated
cells were marked to be followed for 2–3 weeks in culture. When a single colony was formed, it
was transferred to a MW-6 well. Clones were treated for 192–240 hours with the selective
medium (DMEM-LG supplemented with 10% FBS, P/S, 50 mg/ml uridine and d4t 0.5 mM).
At the end of this second selection time, mtDNA levels were determined and compared with
those obtained for 143B.TK- Rho-0 cells (Fig 1).
These treated cells and their Rho-0 clones were stored in liquid nitrogen for further use.
Phenotypic characterization of cells by flow cytometry
Cells were harvested, centrifuged,washed, and counted prior to flow cytometry. Cells were
incubated with 12 antibodies (CD29, CD34, CD45, CD69, CD73, CD90, CD105, CD106,
CD166, CD271, STRO and SSEA4) at optimal amounts added to each tube for 1 h at 4°C. A
control tube for each of the chromogens received equivalent amounts of isotype standards.
Rabbit polyclonal anti-mouse IG-FITC (Dako, Barcelona, Spain) was used as a secondary anti-
body when necessary. 2x104 cells per assay were analyzed on a flow cytometer (FACsCalibur,
BectonDickinson,Madrid, Spain). Results were expressed as mean percentage of positive cells
in three individual experiments (mean ± SD).
Detection of cellular reactive oxygen species (ROS) production
Cells were plated at a density of 8x104 cells per well in MW-6 plates for 24 hours, them the
mediumwas depleted and cells were incubated for one hour prior to the incubation with
2,7-dichlorodihydrofluoresceindiacetate at 10 μM (DCFH-DA, Sigma-Aldrich) for 30 min at
37°C in darkness. Cells were harvested by trypsin release and resuspended in saline solution
prior to analysis by flow cytometry. 104cells per assay were measured by flow cytometry. Data
were analyzed using CellQuest software (BectonDickinson). Results were expressed as median
of fluorescence (AU) and represented three independent experiments.
Detection of mitochondrial membrane potential (MMP, Δψm) and
apoptotic cells
To determinemitochondrialmembrane potential, cells were plated at 8x104 cells per well in
MW-6 plates for 48 hours in DMEMwith 10% FBS. Cells were harvested, washed and resus-
pended phosphate-buffered saline (PBS). To establish the mitochondrial membrane potential,
5 μl of 1,1´,3,3,3´-hexamethylindodicarbo-cyanine iodide (DilC1(5) ImmunoStep, Salamanca,
Spain) was added and incubated for 15 min at 37°C, 5% CO2. To measure the MMP, we used a
lipophilic fluorescent stain for labelingmembranes, DilC1(5). This dye accumulates primarily
in those mitochondria having active mitochondrial membrane potentials. Staining decreases as
the mitochondrial membrane potential is reduced.
For apoptosis, the cells were incubated in the presence of staurosporine at 2 μM for 2 hours.
The basal and staurosporine-conditioned cells were washed and resuspended in 1 X annexin-
binding buffer followed by 5 μl of Annexin V-FITC and 5 μl of propidium iodide (PI) (Immu-
noStep) added to each 100 μl of cell suspension. The cells were then incubated at room temper-
ature for 15 minutes in darkness. Following incubation, 400 μl of 1X annexin-binding buffer
was added prior to analysis by flow cytometrywithin one hour. 104 cells per assay were
Rho-0 Mesenchymal Stem Cell
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measured on a flow cytometer and data obtained were analyzed by CellQuest software (Becton
Dickinson). Analysis of apoptosis was performed by counting cells stained simultaneously with
Annexin V–FITC and PI. This allowed the discrimination of intact cells (Annexin V-FITC and
PI negative) from cells in the early apoptotic state (Annexin V-FITC positive and PI negative)
and late apoptotic state (Annexin V-FITC and PI positive).
Results are expressed as percent of positive cells for each dye and represent the mean of
three independent experiments (mean ± SD).
Mitochondrial respiration
Oxygen consumption (OCR, pmoles/min), an indicator of mitochondrial respiration, was
determined by direct measurement with a SeaHorse XFp Extracellular Flux Analyzer instru-
ment (Seahorse Bioscience, Agilent Technologies, Santa Clara, CA, USA). 2x104 cells per well
were seeded in XF cell culture microplates (Seahorse Bioscience, Agilent Technologies) and
incubated at 37°C with 5% CO2. The next day, the cells were washed with XF assay medium
supplemented with 10 mM glucose and 1 mM pyruvate and placed in a 37°C incubator without
CO2 for 1 hour. OCRwas determined following the manufacturer’s instructions. Briefly, for
the mitochondrial stress test, ports were loadedwith 2 μM oligomycin, an ATP synthase inhibi-
tor, 1 μM carbonyl cyanide p-trifluoromethoxyphenyl-hydrazone or FCCP, an oxidative phos-
phorylation uncoupler, and, finally, a mixture of 2 μM Rotenone, a respiratory complex I
inhibitor and 4 μM Antimycin A, a respiratory complex III inhibitor, was added. Real time
OCRwas averaged and recorded three times during each conditional cycle.
Osteogenic, adipogenic, and chondrogenic differentiation
For osteogenic and adipogenic differentiation, 3x103 cells were seeded in wells of a MW-6 plate
and cultured in growth medium for 24 hours. Osteogenesis was induced by culturing the cells
in Osteogenic DifferentiationMedium (Lonza, Biowhittaker). Adipogenesis was induced by
culturing cells in hMSC Commercial Adipogenic DifferentiationMedium (Lonza, Biowhit-
taker), following the manufacturer's instructions. Cultures were alternated between induction
and maintenance medium every 3 days. Both differentiation processes were maintained for 9
days.
Chondrogenesis was assessed using the micropellet formation (2.5x104) technique [34],
with some modifications. 3a6 and 3a6 Rho-0 cells were detached using trypsin and centrifuged
at 300xg for 10 minutes. The resulting pellet was cultured for 21 days in hMSC Commercial
Chondrogenic DifferentiationMedium (Lonza, Biowhittaker) supplemented with 10 ng/ml
transforming growth factor-β3 (TGFβ-3) (Prospec, Ness-Ziona, Israel). During this process the
culture mediumwas changed every 3 days.
Staining neutral lipids
To confirm adipogenic differentiation capacity, 3a6 cells without treatment (3a6-wt) and 3a6
Rho-0 cells were cultured in adipogenic differentiationmedium and the cells were then fixed in
4% paraformaldehyde (Sigma-Aldrich) for 10 minutes at 4°C, followed by double-staining for
30 minutes with a 1:10000 dilution of a neutral lipid dye, 4,4-Difluoro-2.3,5.6-bis-tetramethy-
lene-4-bora-3a,4a-diaza-s-indacene (LD540), kindly provided by Dr Thiele [35]. This step was
followed by 5 minutes incubation with the nuclear dye 20-(4-Ethoxyphenyl)-5-(4-methyl-
1-piperazinyl)-2,50-bi-1H-benzimidazole trihydrochloride (Hoechst 33258. Sigma-Aldrich).
After washing with PBS, cover slips were mounted on microscopy chamber slides using Glycer-
gel (Dako). Fluorescence was visualized and photographed under fluorescencemicroscopy at
20X (Olympus BX61).
Rho-0 Mesenchymal Stem Cell
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RNA extraction and first strand cDNA synthesis
Total RNA from cell cultures and micropellets was extracted using Trizol1 reagent (Invitro-
gen), following the manufacturer's protocol. For each sample, 1μg of total RNA was reversed
transcribedusing the SuperScript1ViloTM Master Mix (Invitrogen), following the manufac-
turer's instructions.
Quantitative real-time-PCR (qRT-PCR)
Real-time PCR utilized a LightCycler 480-II Instrument (Roche,Mannheim, Germany) with
TaqMan Universal Master Mix (Applied Biosystems). Analysis of the results was carried out
using Qbase+ version 2.5 software (Biogazelle, Gent, Belgium).Gene expression in some cases
was calculated relative to the housekeeping gene (RPL13A) and in other cases relative to the
basal condition. Sequence primers, probe and PCR conditions can be provided upon request.
Statistical analysis
Appropriate statistical analyses were performed using GraphPad Prism v6 software. The results
are reported as mean ± SD. A p value less than 0.05 was considered significant.
Results
Generating Rho-0 cells from 3a6 human immortalized MSCs
Because this is the first time that a hMSC cell line was used to generate cells with depleted
mtDNA, we first tested survivability, as well as capability to becomeRho-0 cells, using classic
methodologywith EtBr. The results showed that the 3a6 cell line cultured with EtBr at 100 nM
for a short time, 240 hours, had a 8.17% decrease of mtDNA copy number compared to 3a6
cells without treatment (3a6-wt, mtDNA copy level was established at 100%) (Fig 2A). These
results demonstrate the capacity of the 3a6 cell line to deplete its mtDNA and survive in culture
in the presence of uridine.
The next set of experiments studied the ability of other reagents less toxic than EtBr to
reducemtDNA copy number. 3a6 cells cultured in the presence of three different Rd6g concen-
trations (1, 3 and 5 μg/ml) for 168 hours showed a small decrease in mtDNA content (Fig 2B).
Rd6g at 3 μg/ml for 120 hours yielded the greatest decrease in the percentage of mtDNA con-
tent, 68.5%. The highest concentration, 5 μg/ml, proved to be the least effective, with the levels
of mtDNA actually increasing compared to cells without treatment (Fig 2B).
The lowest concentration of MPP+, 25 μM, at 72 hours of culture reduced the percentage of
mtDNA copies to 41.41% compared to the control. The other two concentrations, 0.5 mM and
1 mM, produced similar results at the same time (Fig 2C). A culture time longer than 72 hours
with MPP+ induced cell death by necrosis at all concentrations (data not shown).
Interestingly, the capacity of the two nucleosides reverse transcriptase inhibitors (NRTIs)
selected differed. Both AZT concentrations, 20 μM and 0.5 mM, at all culture times, increased
the mtDNA levels and both concentrations showed similar effects on mtDNA copy number
(Fig 2D). However, incubation of cells with Stavudine (d4t) yielded different results. Low con-
centrations (5 and 10 μM) did not produce a decrease in the mtDNA copy number, but high
concentrations, 100 μM and 0.5 mM, incubated for 144 hours decreasedmtDNA copy number
to 10.84% compared to that of the control (Fig 2E). The most effective concentration and cul-
ture times for reducing mtDNA copy number in 3a6 hMSCs are summarized in Table 2.
The values obtained to this point come from a pool of cells; therefore we performed clone
isolation. Cells from the 3a6 cell line were cultured in the presence of d4t at 0.5 mM for about
96 hours before selection of each clone. First, we isolated 15 clones and analyzed the mtDNA
Rho-0 Mesenchymal Stem Cell
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copy number from each. The results showed variability in the mtDNA copy number ranging
from 67.79% (clone-7) to 10.76% (clone-3), compared to 3a6 cells without treatment (3a6-wt)
(Fig 3A). To decrease the mtDNA copy numbers detected in 3a6 clones to values similar to
those described for other Rho-0 cells, such as 143B.TK- Rho-0, two 3a6 clones were selected.
One, C-10, had a highmtDNA copy number; 63.68%, and the other, C-3, the lowest value for
mtDNA copies, 10.76%. Both clones were cultured with uridine (50 mg/ml) and d4t (0.5 mM)
for an additional 192 hours prior to analysis of the mtDNA copy number. The results showed
that both selected clones had obtained a low number of copies when compared to their parental
line, 0.80% for C-3 and 1.57% for C-10, when 3a6 was assigned the mtDNA copy number
value of 100% (Fig 3B). These values are characteristic of Rho-0 cell lines, as shown in the
Fig 2. 3a6 cell line response to different substances capable of depleting the levels of mitochondrial DNA. All mtDNA copy numbers are
expressed as percentages comparing each value with untreated cells valued at 100% (a). Treatment with ethidium bromide (EtBr) at three different
concentrations (1 mM, 100 nM and 500 nM) for 240 hours. The maximum effectiveness of this treatment was at 100 nM. (b). Treatment with
Rhodamine 6g at 1, 3 and 5 μg/ml for 24, 72, 120 and 168 hours. (c). Treatment with 1-methyl-4-phenylpyridinium (MPP+) at 25 μM, 0.5 mM and 1
mM for 72 hours. (d). Treatment with Zidovudine (AZT) at 20 μM and 0.5 mM, for 96, 144 and 216 hours. AZT increased mtDNA content. (e).
Treatment with Stavudine (d4t) at 5, 10 and 100 μM and 0.5 mM for 96 and 144 hours. The analysis of mtDNA copy numbers reflect that treatment
with the highest concentration (0.5 mM) for 144 hours decreased the levels of mtDNA in treated cells nearly 98% compared to those of untreated
cells. 8x104 cells were plated in each experiment for treatment with a reagent. The figures represent at least three independent experiments.
doi:10.1371/journal.pone.0164199.g002
Table 2. Summary of the most effective reagent reducing mitochondrial DNA (mtDNA) copy number in 3a6 human mesenchymal stem cells
(hMSCs).
Drug Concentration Time (Hours) 3a6% mtDNA copy number
Etidium bromide (EtBr) 100 mM 168 8.15
Rhodamine-6g (Rd6g) 3 μg/ml 120 84.97
1-methyl-4-phenylpyridinium (MPP+) 25 μM 72 41.41
Zidovudine (AZT) 0.5 mM 216 221.55
Stavudine (d4t) 0.5 mM 144 2.86
doi:10.1371/journal.pone.0164199.t002
Rho-0 Mesenchymal Stem Cell
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same Fig where the % of mtDNA copy number in the 143B.TK-Rho-0 line (0.284%) is com-
pared to that of its parental cell (143B.TK-) (100%).
To test the ability of the selected clones to grow in culture mediumwithout d4t and main-
tain the mtDNA levels of a Rho-0 cell line, we cultured C-3 cells (pre-treated for 192 h with d4t
at 0.5 mM) for 288 hours in a culture medium supplemented only with uridine.We then iso-
lated the total DNA at 48, 72, 120, 240 and 288 hours of culture and assessed the mtDNA copy
number. The results showed that these cells maintained low levels of mtDNA (Fig 3C). These
results indicate that the clones isolated from 3a6 are Rho-0 cells and could be used to construct
transmitochondrial cybrids. The C-3 clone was selected for use in further experiments.
Because all reagents do not possess the same capability for removing mtDNA in different
cell lines, we examined the ability of these reagents in another hMSC cell line generated from
Fig 3. Clone Selection. (a). The mitochondrial DNA (mtDNA) copy number of 15 clones isolated by limit dilution from 3a6 cells
treated with Stavudine (d4t) at 0.5 mM for 240 hours. Data for clones are expressed as percentages of untreated cells [without
treatment (wt), value 100%]. (b). mtDNA copy number of two selected clones, one with low mtDNA (C-3; 1.57%) and the other
with a high value for this parameter (C-10; 0.80%). Both clones were re-treated with d4t at 0.5 mM for 192 hours with mtDNA
copy number expressed as a % of that of the 3a6 parental line. In this graphic, the %mtDNA copy number for 143B.TK- Rho-0 is
also represented in relation to that of its parental cell line (143B.TK-). (c). This graph shows the % of mtDNA copy number for C-3
cultured in DMEM without d4t for 288 hours. The results show the stability of the mtDNA copy number during culture without the
drug.
doi:10.1371/journal.pone.0164199.g003
Rho-0 Mesenchymal Stem Cell
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the same cell line donor as 3a6. We used the KP cell line to evaluate the efficiencyof the com-
pounds tested on 3a6. We first determined the ability of KP cells to become Rho-0 cells. The
results indicated that KP cells incubated with EtBr at 500 nM for 168 hours showed decreased
levels of mtDNA copy number, 8.93%, compared to cells without treatment (KP control at
100%) (Fig 4A). Rd-6g (3 μg/ml) lowered the mtDNA content beginning on the second day
of exposure, the level of mtDNA at 96 hours being 8.34% (Fig 4B). The capacity of NRTIs in
KP cells was similar to that in 3a6 cells. Culture with AZT producedmtDNA levels above
100%, except for 10 μM at 240 hours, at which concentration and time mtDNA levels
decreased to near 60% (Fig 4C). Three concentrations of d4t were tested (5 μM, 10 μM and
0.5 mM) over 240 hours of culture and mtDNA levels decreased to 12.38% at 0.5 mM con-
centration (Fig 4D). The most effective concentration and time of culture of the conditions
tested to reduce mtDNA copy number in the KP mesenchymal stem cell line are summarized
in Table 3.
Fig 4. The response of the KP cell line to different substances that deplete mitochondrial DNA. All mtDNA
copy numbers are expressed as percentages compared to those of untreated cells valued at 100%. (a). Treatment
with ethidium bromide (EtBr) at three different concentrations, 1 mM, 500 nM and 100 nM, for 240 hours. (b).
Treatment with Rhodamine6g (Rd6g) at 3 μg/ml for 24, 48, 72 and 96 hours; the positive response started at 48
hours. (c). Treatment with Zidovudine (AZT) at 10 μM and 0.5 mM for 168 and 240 hours. (d). Treatment with
Stavudine (d4t) at three concentrations, 5 μM, 10 μM and 0.5 mM, for 240 hours. 8x104 cells were plated in each
experiment for treatment with different agents. The figures represent at least two independent experiments.
doi:10.1371/journal.pone.0164199.g004
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Characterization of Rho-0 hMSC cells
To assess whether 3a6 Rho-0-like cells maintain the stem properties of 3a6-wt cells, a pheno-
typic characterization was developed. FACS analysis demonstrated that 3a6-wt and 3a6 Rho-0
cells showed a similar cell-surface receptor pattern (Fig 5A). Both types of cells were negative
for CD34, CD45, CD69, CD106, CD271 and STRO antigens (data not shown). In both 3a6-wt
and 3a6 Rho-0-like cells nearly 95% of the cells were positive for CD29, CD73, and CD90. Sig-
nificant differences existed for CD105 (3a6-wt: 51.96±16.07%; 3a6 Rho-0-like: 17.99±1.80%,
p<0.05) and SSEA4 (3a6-wt: 20.45±3.52%; 3a6 Rho-0-like: 79.01±3.92%, p<0.0001).
The assessment of ROS production showed no significant differences between 3a6-wt, 3a6
Rho-0 and 143B.TK- Rho-0 cells (Fig 5B). While levels of apoptosis did not differ in numbers
of positive cells between basal conditions and Staurosporine exposure in 3a6-wt and 3a6 Rho-0
cells, for 143B.TK- Rho-0 cells the difference was statistically significant (basal: 10.11%±2.67;
Staurosporine 32.20%±7.36, p<0.05) (Fig 5C).
The mitochondrial membrane potential (Δψm) of 3a6 Rho-0 cells showed a significant
decrease compared to that of 3a6-wt cells (3a6-wt: 95.66±1.86%; 3a6 Rho-0: 68.11±1,62%;
p0.05). Similarly, the Δψm of the 143.B TK- Rho-0 cell line significantly decreased compared
to that of 3a6-wt cells (3a6-wt: 95.66±1.86%; 143B. TK- Rho-0: 68.50±5.37%; p0.001) (Fig
5D).
The mitochondrial network was broken in the 3a6 Rho-0 cells and mitochondria were
rounded and surrounded the nucleus when compared with 3a6-wt cells (Fig 5E). The 3a6 Rho-
0 cells had a lower basal OCR and did not respond to the administration of oligomycin, FCCP
and rotenone/antimycin while parental cells showed standard values. These results are similar
to those found for 143B.TK- and 143B.TK-Rho-0 cells (Fig 5F and 5G).
Differentiation capacity of Rho-0 hMSCs
To evaluate the multipotential capacity of Rho-0 hMSCs, we examined the expression of
Nano-HomeoBox (Nano-g), POU Class 5 Homeobox 1 (Oct 3/4), SRY (Sex determining
region)-Y-box 2 (Sox-2) and SRY-box 9 (Sox-9). The results of the q-PCR analyses revealed
that the expression levels of the four genes in 3a6-Rho-0 cells were significantly lower than
those in 3a6-wt cells (p0.05) (Fig 6A).
Another set of experiments was designed to study how reducing the expression of the above
mentioned four genes affects the capacity of 3a6 Rho-0 cells to differentiate into osteocytic, adi-
pocytic and chondrocytic cellular lineages.
Basal expressions of two genes involved in osteogenesis, alkaline phosphatase-4 (ALP) and
osteocalcin-1 (OC-1), did not show any significant difference between 3a6 Rho-0 and 3a6-wt
cells (Fig 6B). However, their expression after 9 days in culture with specific differentiation
medium showed that ALP expression was higher in 3a6 Rho-0 than 3a6-wt cells (0.575
±0.035-fold for 3a6-wt and 1.701±0.156-fold for 3a6 Rho-0). Expression levels of OC-1 after
osteogenesis induction did not show significant differences between the two cell types (Fig
6C).
Table 3. Summary of the most effective reagent, in KP human mesenchymal stem cells (hMSCs).
Drug Concentration Time (Hours) KP % mtDNA copy number
Etidium bromide (EtBr) 500 mM 168 8.93
Rhodamine-6g (Rd6g) 3 μg/ml 96 8.34
Zidovudine (AZT) 10 μM 240 59.68
Stavudine (d4t) 0.5 mM 240 12.38
doi:10.1371/journal.pone.0164199.t003
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Fig 5. Characterization of 3a6 cells without treatment (3a6-wt) and 3a6 Rho-0 like cells. (a). Phenotypic characterization is
represented as the percentage of positivity for CD29, CD73, CD90, CD105, CD166 and SSEA4 for both cell types. (b). Cellular levels of
reactive oxygen species (ROS) in both cell types and in 143B.TK-Rho-0 cells (used as a reference for a typical Rho-0 line). Total ROS
production was measured with 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA); data are expressed as mean fluorescence
intensity. (c). Apoptosis measured with Annexin-V-FIT: data are expressed as percentage of positive cells for Annexin-V and propidium
iodide (PI) in basal conditions and culture in presence of Staurosporine (Stau) at 2 μM for 2 hours. (d). Mitochondrial membrane
potential (Δψm) measured with DilC1(5) [1,1´,3,3,3´-hexamethylindodicarbo-cyanine iodide], data are expressed as percentages of
cells that were positive for DilC1(5) fluorescence. (e). Mitochondrial network in 3a6-wt and 3a6-Rho 0 cells incubated with 250 nM
MitoTraker Red solution for 30 min in a 37˚C incubator. The cells were fixed with 4% paraformaldehyde and counterstained with
Hoechst-33258 nuclear dye. The cells were photographed with a confocal microscope Nikon AR-1. (f-g) The mitochondrial respiration
[oxygen consumption (OCR)] pattern was obtained using a SeaHorse XFp for 3a6-wt and 3a6 Rho-0 cells (f) and for 143B.TK- and
143B.TK-Rho-0 cells (g). All data were obtained from three independent experiments, expressed as mean ±SD and analyzed by the
unpaired t-test (*, p0.05; *** p<0.001).
doi:10.1371/journal.pone.0164199.g005
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Fig 6. Osteogenic, adipogenic and chondrogenic differentiation in 3a6 without treatment (3a6-wt) and 3a6 Rho-0 cells. (a) Gene
expressions implicated in the non-differentiation stage: Nano-HomeoBox (Nano-g), POU Class 5 Homeobox 1(Oct 3/4) and SRY (Sex determining
region)-Y-box 2 (Sox-2) and SRY (Sex determining region)-Y-box 9 (Sox-9) in 3a6-wt and 3a6 Rho-0 cells. (b). Gene expressions implicated in the
osteogenic process: alkaline phosphatase-4 (ALP) and osteocalcin-1 (OC-1) in basal condition in 3a6-wt and 3a6 Rho-0 cells. (c). Fold increase in
the gene levels of ALP and OC-1 during osteogenic induction for 9 days; data are expressed relative to the basal condition (basal condition equal to
1). (d). Basal gene expressions implicated in the adipogenic process: fatty acid synthase (FASN) and peroxisome proliferator-activated receptor
gamma (PPAR-γ) in 3a6-wt and 3a6 Rho-0 cells. (e). Fold increase in the gene levels of FASN and PPAR-γ following 9 days under adipogenic
differentiation; data are expressed relative to the basal condition (basal condition equal to 1). (f). LD540, which stains lipid droplets, was used to
measure adipogenic differentiation in 3a6-wt and 3a6 Rho-0 cells. Cells were cultured in standard medium (control) and in adipogenic medium for 9
days. Cells were fixed and double-stained with LD540 (red) for lipid droplets and Hoechst 33258 (blue) for DNA. Fluorescence was visualized with
Olympus BX61 fluorescence microscopy and photographed at 20X. (g). Fold increase in the gene levels of CoL-I and CoL-II in the micropellet model
following 21 days under chondrogenic differentiation; data are expressed relative to the basal condition (basal condition equal to 1). All data were
obtained from three independent experiments, expressed as mean ±SD and analyzed by the unpaired t-test (*, p0.05; ** p<0.005). Basal, without
induction. Osteo (Osteogenic), Adipo (Adipogenic), Chondro (Chondrogenic) cells grown in the presence of indicated medium.
doi:10.1371/journal.pone.0164199.g006
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Basal expression of the fatty acid synthase (FASN) gene was similar in both 3a6-wt and
3a6-Rho-0 cells. The basal expression of peroxisome proliferator-activated receptor gamma
(PPAR-γ) was higher in 3a6-wt than 3a6 Rho-0 cells, but not significantly so (Fig 6D). Interest-
ingly, in 3a6-wt cells, the induction of adipogenesis differentiation did not modify the expres-
sions of FASN and PPAR-γ (0.558±0.13-fold for FASN and 0.522±0.113-fold for PPAR-γ).
However, differentiated 3a6 Rho-0 cells showed a significant increase in the levels of both
genes (FASN: 2.45±0.14-fold, p0.005; PPAR-γ: 9.334±1.32-fold, p0.01) (Fig 6E). These
results were confirmed by staining cells with LD540; cells cultured in adipogenicmedium
showed more neutral lipid in 3a6 Rho-0 cells than in 3a6-wt cells (Fig 6F).
To analyze the capacity of these cells to differentiate into chondrocytes,micropellet forma-
tion under chondrogenic differentiation was employed and the gene expression levels of CoL-I
and CoL-II were evaluated. The results showed that chondrogenic differentiation increased the
levels of CoL-1, but with statistical significance only in the case of 3a6 Rho-0 cells (44.38
±10.28, p0.05). The levels of CoL-II increasedmore in 3a6-wt than in 3a6 Rho-0 cells (Fig
6G).
To examine the extent of mitochondrial activity involvement in the cellular differentiation
process, the expression levels of two genes indicative of mitochondrial biogenesis, peroxisome
proliferator-activated receptor gamma co-activator 1-alpha (PGC-1α) and transcription factor
A mitochondrial (TFAM) were determined. The basal expression level of both genes was simi-
lar in 3a6-wt and 3a6 Rho-0 cells, but the basal genetic expression of PGC-1αwas significantly
higher in 3a6-wt than in 3a6 Rho-0 cells (p<0.01) (Fig 7A).
The gene expression level of PGC-1α after 9 days in culture with specific adipogenic
medium in comparison with cells cultured in basal medium showed that its expression was sig-
nificantly higher in 3a6 Rho-0 adipogenic than in basal condition (3a6 Rho-0-Adipo: 10.82
±1.082-fold vs. 3a6 Rho-0-Basal p0.005) (Fig 7B). Similar results (but not significant) were
obtained for TFAM gene expression (Fig 7C).
Discussion
The first successful isolation of human Rho-0 cells used long-term exposure to EtBr of cells
from the 143B.TK- cell line [16]. These authors found that growth of cells obtained by this
method is uridine- and pyruvate-dependent because of the absence of a functional respiratory
chain. To date, most Rho-0 cells used to construct cybrids have been generated following this
procedure.We have, in this work, used EtBr to evaluate the capacity of cells of a hMSC line to
becomeRho-0 cells and survive. Our results confirm the capability of EtBr to deplete mtDNA
in hMSCs and, furthermore, the ability of these depleted cells to survive with very low copies of
mtDNA in culture containing uridine. However, EtBr is an intercalating agent that causes neg-
ative effects in the nuclear genome; therefore, we consequently analyzed other compounds
with the aim of reducing the number of mtDNA copies with less toxicity. We examined the
karyotype of these depleted cells and have shown that the compounds used to produce 3a6
Rho-0 cells do not induce change in the number and in the size of chromosomes. Both 3a6-wt
and 3a6 Rho-0 cell types have similar chromosome conformation and their karyotypes are sim-
ilar (data are not presented).
The first compound tested was Rhodamine 6g (Rd6g), which, in vivo penetrates into the cell
and binds to the inner membranes of the mitochondria, decreasingmitochondrial enzymatic
activity. This inhibits oxidative phosphorylation and reduces the number of intact and meta-
bolically active mitochondria within the cell [24]. Rd6g has been used to remove mitochondrial
DNA from cells in culture for the construction of cybrids or hybrids using hamster [36], mouse
[37] and human skin fibroblasts [38]. Our results showed that Rd6g is less effective for
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removing mtDNA in hMSC cell lines, although in KP cells Rd6g produced a larger decrease of
mtDNA copy number, but this reduction was not sufficient to generate Rho-0 cells. It is possi-
ble that Rd6g causes rapid and irreversible damage to mitochondria without removing mtDNA
[38,39].
Another compound tested to reduce mtDNA from 3a6 hMSCs was MPP+. This molecule
inhibits mtDNA replication by preventing incorporation of 5-bromo-20-deoxyuridine into
mitochondrial, but not into nuclear DNA [27,29]. Data generated by several studies suggested
that MPP+ does not affect the overall biogenesis of mitochondria becausemitochondrial tran-
scription factor A is not decreased in treated cells. Thus, MPP+ selectively inhibits the replica-
tion of mtDNA, decreasing the intracellular content of mtDNA in treated cell lines
[27,29,40,41]. In our work, 3a6 hMSCs could survive in the presence of MPP+ for only a short
time. The results of the effect of MPP+ described in the literature demonstrated that MPP+
Fig 7. mRNA expression of mitochondrial biogenesis genes in 3a6 without treatment (3a6-wt) and 3a6
Rho-0 cells. (a). To analyze mitochondrial biogenesis, peroxisome proliferator-activated receptor gamma
coactivator 1-alpha (PGC-1α) and transcription factor A, mitochondrial (TFAM) gene expression levels were
determined under basal conditions. (b). Fold increase of PGC-1α gene levels during osteogenic and adipogenic
induction. and (c). TFAM gene levels during osteogenic and adipogenic induction. Data are expressed relative to
basal condition (basal condition equal to 1). All data were obtained from two independent experiments, expressed
as mean ± SD and analyzed by the unpaired t-test (* p<0.05; ** p<0.005). Basal, in standard medium, Adipo
(Adipogenic) and Osteo (Osteogenic); all experiments were developed during 9 days in each specific
differentiation culture medium.
doi:10.1371/journal.pone.0164199.g007
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initiated lipid peroxidation, stimulated ROS production and decreasedATP levels, all processes
implicated in the cell death induced by this compound [27] and indicating potent cellular tox-
icity in hMSCs.
The other two compounds tested (AZT and d4t) are NRTIs, a group of drugs used in the
treatment of AIDS associated with lipodystrophy. The prevailing hypothesis for their toxicity
suggests that these drugs inhibit mtDNA polymerase γ [26,42]. AZT inhibits thymidine phos-
phorylation and may deplete intracellular thymidine-5´-triphosphate (TTP) to generate an
imbalance betweenTTP and other deoxynucleotides [43–46]. In our study with hMSCs, AZT
increasedmtDNA content in both 3a6 and KP cell lines, in agreement with results obtained by
other authors [43,47]. Although the mechanisms through which AZT increasedmtDNA are
unknown, some studies have indicated that this compound up-regulates genes encoding
mtDNA [48]. Other authors have suggested that the mechanism is a compensatory response to
mitochondrial dysfunction, which includes inhibition of mtDNA polymerase γ [47], oxidative
stress [49] and increasedmitochondrial mass because of oxidative stress [50,51]. Another
NRTI thymidine analogue, potentially much more toxic to polymerase γ [42,52], is Stavudine
(d4t). Our results are in agreement with previous reports [43,53] that d4t induced significant
reduction of the mtDNA copy number in both hMSC cell lines analyzed compared to cells
without treatment. The mitochondrial copy number in 3a6 cells treated with d4t (3a6 Rho-0:
8.3±3.01) is in a similar range of values obtained with 143B.TK-Rho-0 cells (4.11±1.97); both
values were calculated using the previously describedmethods. In addition, the low copy num-
ber of mtDNA was maintained for 288 hours after removing d4t from the hMSC culture.
These data support the stability of the low number of mtDNA copies even in the absence of
drug. The mitochondrial network was broken when 3a6 cells became 3a6 Rho-0 cells. The
mitochondrial morphology changed and the mtDNA depletion inducedmitochondrial frag-
mentation like that described in other Rho-0 cell lines generated by other methods [54,55]. The
data obtained on mitochondrial respiration indicated that the 3a6 Rho-0 cells generated in this
work have greatly impaired respiration, like that of a typical Rho-0 cell line [54,55]. All these
characteristics indicate that hMSCs cultured with d4t are really Rho-0 cells.
Because the results confirm that 3a6 hMSCs can become 3a6 Rho-0 cells, it was necessary to
show that these cells continue beingMSCs. To confirm the MSC phenotype, cell surface recep-
tor patterns were studied in both 3a6-wt and 3a6 Rho-0. The results showed a similar receptor
pattern for four receptors in both cell types, but 3a6 Rho-0 had a lower percentage of CD105.
However, this value agrees with the value for this receptor in the parental cell line (3a6) [33]
and in the original cell line from which the KP cell line was obtained, which had levels of
CD105 less than 20% [32]. In addition, 3a6 Rho-0 showed high levels of SSEA. Taken together,
these findings suggest that hMSC Rho-0 cells still express the characteristicMSC phenotype
pattern.
ROS production was assessed using flow cytometrywith the results showing the same level
of ROS for both 3a6-wt and 3a6 Rho-0 cells. These data differ from previous studies reporting
that Rho cell lines and their parental cell lines produce different levels of ROS [56,57]. How-
ever, the ROS level of 3a6 Rho-0 cells is very similar to the ROS level of classical Rho-0 cells
(143B.TK-Rho-0). It is possible that the capacity of 3a6 hMSCs to produce ROS is lower than
the differentiated cell lines used in other studies [56].
Survival and the percentage of apoptosis in both 3a6-wt and 3a6 Rho-0 cell lines were simi-
lar. 3a6 Rho-0 cell growth was dependent on uridine as shown previously in other Rho-0 cell
lines. The percentage of apoptotic cells with uridine exposure showed a normal number of apo-
ptotic cells. The induction of apoptosis with staurosporine was also similar for both cell types.
These data indicate that the generated cells have normal viability in culture and are suitable for
study of the role of mitochondria in apoptosis.
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The lower mitochondrial membrane potential (Δψm) of 3a6 Rho-0 cells compared to
3a6-wt cells agrees with the results from another Rho-0 cell line when compared with parental
cells. For example, 143B.TK-Rho-0 had 36% less Δψm than 143B.TK-. However, the Δψm of
other Rho-0 lines (HepG2 and HeLaS3), did not reflect differences from their parental cells
[58]. Several authors have shown that Rho-0 cell lines maintain the Δψm because it is necessary
for growth [59] and that the Δψm is maintained by a residual proton gradient [60–62]. Assum-
ing that the mitochondrial electron transport chain (ETC) is the major source of intracellular
ROS, the results indicated that the ETC works well in cells that had been depleted of their
mtDNA, in line with the results obtained by Δψm.
The methodologies described in this work were tested in hMSCs from primary bone mar-
row and synovial tissue cultures. Analyses of Rd6g and d4t efficiency in hMSCs from primary
cultures revealed differences in efficiencydepending on the patient (data not shown). However,
the most important limitation of using hMSCs from primary culture was their limited ability
for expansion under standard conditions, especially with increasing age of the patient [28,29]
and rapid senescence in culture [30,31].
The protocols describedhere allowed us to generate Rho-0 cells from hMSCs avoiding some
typical inconveniences from using tumour cells, such as aneuploidy. This characteristic varies
extensively among different Rho-0 cell lines [18–20] and, to date, it is not clear how aneuploidy
impacts mitochondrial function. In addition, we tested several compounds and protocols to
avoid using EtBr, a compound with very important toxic effects on population health. Among
the compounds and conditions tested in this work, we suggest that d4t exposure at 0.5 mM for
240 hours is the best protocol to generate Rho-0 cells from 3a6 and KP hMSCs (Tables 2 and
3).
We also evaluated the effect of depletion of mtDNA on stem cell-like properties. Our data
suggest a decrease of stem-like potentiality during mtDNA depletion. Some researchers have
shown a relationship betweenmtDNA and the level of DNA methylation [63–65]. Recent evi-
dence using a global assessment of DNA methylation found that cells depleted in mtDNA
showed altered DNA methylation of the nuclear genome [64]. This findingmay help explain
our finding differences in the expression of several genes involved in MSC differentiation from
3a6-wt to 3a6 Rho-0, but additional work will be needed to confirm this.
Core pluripotency, including Nanog, Oct-4 and Sox-2, share points of convergence with
STAT3, a master metabolic regulator controlling the oxidative glycolytic switch [66–69]. 3a6
Rho-0 cells have a lower expression of these genes than 3a6-wt cells. Taking into account that
the transition from glycolysis to mitochondrial oxidative metabolism and maintenance of
mitochondrial electron transport function are critical for differentiation [64,68], perhaps 3a6
cells will have more difficulty to respond under mesenchymal induction.
hMSCs are somatic stem cells with the capacity to differentiate into multiple lineages,
including osteoblasts, adipocytes and chondrocytes. In this work we evaluated whether the
mtDNA-depleted 3a6 Rho-0 cell line could differentiate into osteoblasts, adipocytes and chon-
drocytes. The results indicated that both 3a6-wt and 3a6 Rho-0 cell lines could be induced to
differentiate under defined culture conditions, but the capacity for response was different.
Osteogenic and chondrogenic differentiation was more effective in 3a6-wt than in 3a6 Rho-0
cells, while adipogenesis was more effective in 3a6 Rho-0 cells. A possible explanation could be
that metabolic changes in hMSCs may differ drastically depending on which lineage they are
induced to differentiate [70]. The genetic expression levels analyzed were low, probably due to
the short induction time, although 9 days was described in the literature as an optimal time for
evaluating the differentiation process in hMSCs. The expression of the OP gene was detected
14 days after induction, while PPAR-γ was detected 7 days after induction in the KP cell line
[32]. OC expression was positive in 3a6 cells after 14 days in osteogenicmedium [33]. We
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followed the differentiation for 9 days to analyze the differentiation capacity of 3a6 Rho-0 cells
compared to 3a6 cells. Perhaps an in-depth analysis of the differentiation process under longer
differentiation time would be interesting.
The different values for CD105 between 3a6-wt and 3a6 Rho-0 cells might reflect a different
chondrogenic capacity of both cell types, as recently describedby Fan and coworkers, who
found that CD105 promotes chondrogenesis in MSCs obtained from synovium [71]. This data
opens several new areas for research.
Several authors have described that during hMSC osteogenic and adipogenic differentiation
there is a well coordinated process involving up-regulation of the biogenesis and respiratory
function of mitochondria and expression of antioxidant enzymes. [66,67,72]. Mitochondrial
biogenesis has been shown to be essential for adipogenic differentiation of the 3T3 mouse
embryonic fibroblast cell line [73]. Knowing the metabolic switch during hMSC differentiation
is dependent on increasedmitochondrial activity, the analyses of PGC1α, a key for mitochon-
drial biogenesis, and TFAM, a transcription factor that binds to the mitochondrial genome,
increasing their replication and mitochondrial gene expression in differentiation processes,
were performed in 3a6-wt and 3a6 Rho-0 cells. PGC1α and TFAM gene expressions were
increased during the differentiation process, and this increase was higher in 3a6 Rho-0 cells
under adipogenic induction. This suggests that, during differentiation, an increase in mito-
chondrial mass could result from increased biogenesis beingmore significant in cells with low
levels of mtDNA copy number.
This data is in line with that of other groups, who showed that when the mtDNA copy num-
ber was analyzed during differentiation, a dynamic change upon induction occurred.One
explanation for this could be that down-regulation of glycolysis genes and activation of respira-
tory genes by PGC-1α increased the mtDNA [69,72]. The results shown here conformed to the
idea that the mitochondria and bioenergetic functions play an important role in stem cells and
in their differentiation process.
In summary, this is the first study to describe a protocol for the generation of Rho-0 cells
using immortalized hMSCs and alternative compounds to EtBr. Because the generation of
Rho-0 cells is the first step to construct cybrids, we suggest the use of hMSCs as nuclear donors.
This model will allow study of the role of mitochondria as well as the different mtDNA hap-
logroups (or mtDNA SNPs) in the differentiation process. In addition, it will be possible to
analyze the role of mitochondrial SNPs in specific cells obtained from hMSC differentiation.
Several studies have shown that hMSCs are dependent on glycolysis for energy supply, but
quickly shift to aerobic metabolism once they are induced to undergo differentiation. To our
knowledge no one has published results like ours analyzing the mitochondrial role during the
differentiation process.
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